Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis.

Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. · 2017

Read Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. by Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5574616.txt.

Introduction

Lavia and co-authors present a systematic review and meta-analysis in PLoS ONE. Their subject is minimally invasive glaucoma surgery, called MIGS. These small procedures lower eye pressure in open angle glaucoma. They aim to be safer and gentler than classic filtration surgery.

The search found nine trials and 21 case series, with 2,928 eyes in all. Devices studied include the iStent, Trabectome, CyPass, and XEN. In before-after series, MIGS cut eye pressure and drug use. Safety looked good, with pressure spikes the most common problem. No infections were reported. Most proof came from studies without control groups, though. The authors call for better trials. Readers get a careful map of a fast-growing field.

Catalog record

CREATORLavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE68 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5574616

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis By Carlo Lavia, Laura Dallorto, Milena Maule, Manuela Ceccarelli, Antonio Maria Fea, Gianni Virgili Published in: PLoS ONE DOI: 10.1371/journal.pone.0183142 ABSTRACT Background MIGS have been developed as a surgical alternative for glaucomatous patients. Purpose To analyze the change in intraocular pressure (IOP) and glaucoma medications using different MIGS devices (Trabectome, iStent, Excimer Laser Trabeculotomy (ELT), iStent Supra, CyPass, XEN, Hydrus, Fugo Blade, Ab interno canaloplasty, Goniscopy-assisted transluminal trabeculotomy) as a solo procedure or in association with phacoemulsification. Methods Randomized control trials (RCT) and non-RCT (non randomized comparative studies, NRS, and before-after studies) were included. Studies with at least one year of follow-up in patients affected by primary open angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma were considered. Risk of Bias assessment was performed using the Cochrane Risk of Bias and the ROBINS-I tools. The main outcome was the effect of MIGS devices compared to medical therapy, cataract surgery, other glaucoma surgeries and other MIGS on both IOP and use of glaucoma medications 12 months after surgery. Outcomes measures were the mean difference in the change of IOP and glaucoma medication compared to baseline at one and two years and all ocular adverse events. The current meta-analysis is registered on PROSPERO (reference n° CRD42016037280). Results Over a total of 3,069 studies, nine RCT and 21 case series with a total of 2.928 eyes were included. Main concerns about risk of bias in RCTs were lack of blinding, allocation concealment and attrition bias while in non-RCTs they were represented by patients’ selection, masking of participants and co-intervention management. Limited evidence was found based on both RCTs and non RCTs that compared MIGS surgery with medical therapy or other MIGS. In before-after series, MIGS surgery seemed effective in lowering both IOP and glaucoma drug use. MIGS showed a good safety profile: IOP spikes were the most frequent complications and no cases of infection or BCVA loss due to glaucoma were reported. Conclusions Although MIGS seem efficient in the reduction of the IOP and glaucoma medication and show good safety profile, this evidence is mainly derived from non-comparative studies and further, good quality RCTs are warranted. INTRODUCTION Glaucoma is the second commonest cause of blindness worldwide [1]. To date, the main treatment for preventing glaucomatous damage consists in lowering intraocular pressure (IOP)[2]. The first ocular hypotensive approach is commonly eye-drop medications, whose instillation is often needed more than once per day. Poor compliance [3–4] and tolerability [5–6] can sometimes lead to treatment failure. Ab externo filtration surgery is still considered the gold standard but it is reserved to progressive disease and may lead to significant complications [7,8]. Minimally-invasive glaucoma surgeries (MIGS) have been developed as safer and less traumatic surgical interventions for patients with mild to moderate glaucoma or who are intolerant to standard medical therapy [9]. According to the commonly accepted definition, MIGS are surgical procedures with an ab-interno approach, minimal trauma with very little or no scleral dissection, minimal or no conjunctival manipulation, good safety profile and rapid recovery [10]. MIGS devices can be divided in: trabecular, suprachoroidal and subconjunctival based [11]. They can be performed in association with cataract surgery or as a solo procedure [12]. The trabecular based devices work by improving trabecular outflow through Schlemm's canal. The suprachoroidal based devices improve the uveoscleral outflow through a connection between the anterior chamber and the suprachoroidal space while the subconjunctival devices create an alternative outflow pathway of the aqueous humor to the subconjunctival space [13,14]. There is a growing interest about MIGS procedures and several clinical studies have been published in the past years. This increase in surgical options should be supported by a clear evidence of their efficacy, to give the surgeon a detailed panorama on the potential surgical options. However, many clinical studies have been small, nonrandomized, and often lacking appropriate control arms. Moreover, these studies often exhibit great variability in measured outcomes, definition of success/failure and follow-up periods. The purpose of the current meta-analysis is to analyze available data on MIGS and to summarize and quantify their effect on both intraocular pressure and use of topical glaucoma medications as well as their safety profile. MATERIALS AND METHODS In this research, we adhered to the Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Protocol and registration The current meta-analysis is registered on PROSPERO (reference n° CRD42016037280) and is available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016037280. During the peer-review process, extensive changes were required to the original protocol. Literature search strategy The construction of search strategies was performed by an expert epidemiologist (MC) using database specific subject headings and keywords. Electronic databases search was performed by two clinicians (LD, CL) and a third member (AF) in case of disagreement. Articles published between January 1, 2000 and December 31, 2016 were included. Information sources included: MEDLINE Daily and MEDLINE (Ovid), MEDLINE In-Process and Other Non-Indexed Citations, CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register), EMBASE (Ovid), Latin American and Caribbean Literature on Health Sciences (LILACS), CINAHL (EBSCO), Trip Database and The National Institute for Health and Care Excellence (NICE). The search strategies for MEDLINE are included in the supplementary material (S1 Appendix). These searches were supplemented by hand searching the bibliographies of all the included studies. Grey literature was not considered in this meta-analysis due to excessive lack of essential information that usually affects this type of research. Study selection Study design: Randomized controlled trials (RCT) and non-RCT (non-randomized comparative studies, NRS, and before-after studies) were included. Accepted languages of publication were: English, German, French, Spanish, Portuguese and Italian. Exclusion criteria: - Follow-up shorter than 12 months. - Glaucoma types other than primary open angle glaucoma (POAG). pseudoexfoliative (PEX) and pigmentary glaucoma (PG). - Number of patients lost at follow-up equal or greater than 15% (in non RCT studies) - Any previous glaucoma surgery except laser trabeculoplasty. - Studies including patients younger than 18 years. Interventions: In accordance with the provided definition of MIGS we included studies regarding: - Ab interno trabeculotomy, Trabectome device (NeoMedix, Tustin, CA, USA) - Trabecular Microbypass Stent (iStent, Glaukos, Laguna Hills, CA, USA) - Schlemm’s Canal Scaffold (Hydrus, Ivantis, Irvine, CA, USA) - Suprachoroidal Microstent (Cypass Transcend Medical, Menlo Park, CA, USA) - iStent Supra (iStent, Glaukos, Laguna Hills, CA, USA) - XEN Subconjuntival Implant gel stent (Aquesys, Aliso Viejo, CA, USA/ Allergan, Irvine, CA, USA) - Ab interno Canaloplasty (ABIC) - Excimer Laser Trabeculotomy (ELT, Glautec AG, Nurnberg, Germany) - Gonioscopy-Assisted Transluminal Trabeculotomy (GATT) - Fugo plasma blade (MediSurg Research and Management Corp., Norristown, PA, USA) Studies about MIGS as a solo procedure or combined with cataract surgery were considered. Screening of titles and abstracts was carried out and not pertinent articles were rejected. Full texts of residual articles were evaluated independently for eligibility. The process was made according to the PRISMA flow diagram. Duplicates were removed using EPPI reviewer (by EPPI-Center, Social Science Research Unit, the Institute of Education, the University of London, UK). Data collection and risk of bias assessment The main outcome of this meta-analysis was the effect of MIGS devices compared to medical therapy, cataract surgery, other glaucoma surgeries and other MIGS on the change in both IOP

Read the complete text